Top Page
Avicanna
(TSX:AVCN)
Avicanna (AVCN) vs. S&P 500 (SPY)
Avicanna Business Overview & Revenue Model
Avicanna Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 16.79M | 4.05M | 3.27M | 1.57M | 168.25K | Gross Profit |
| 6.66M | 1.12M | 2.83M | -570.12K | 92.14K | EBIT |
| -7.93M | -10.58M | -10.83M | -18.53M | -22.77M | EBITDA |
| -7.36M | -12.18M | -15.13M | -33.70M | -22.27M | Net Income Common Stockholders |
| -8.74M | -17.22M | -16.77M | -32.86M | -22.21M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 477.20K | 1.19M | 31.00K | 2.52M | 441.76K | Total Assets |
| 21.97M | 17.62M | 22.30M | 30.16M | 45.16M | Total Debt |
| 1.80M | 3.21M | 1.66M | 1.94M | 1.27M | Net Debt |
| 1.33M | 2.02M | 1.63M | 671.18K | 829.21K | Total Liabilities |
| 14.00M | 14.16M | 15.39M | 16.25M | 15.29M | Stockholders Equity |
| -112.50K | -383.56K | 1.15M | 6.02M | 22.39M |
| Cash Flow | Free Cash Flow | |||
| -1.96M | -7.50M | -12.45M | -15.43M | -26.94M | Operating Cash Flow |
| -1.40M | -7.44M | -11.66M | -13.97M | -19.45M | Investing Cash Flow |
| -3.05M | 810.24K | 760.83K | -2.71M | -7.49M | Financing Cash Flow |
| 3.55M | 9.90M | 10.06M | 17.39M | 27.31M |
Avicanna Technical Analysis
Avicanna Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $982.82M | 17.65 | 3.80% | ― | 35.87% | ― | |
55 Neutral | $200.75M | ― | -18.27% | ― | 7.33% | 84.41% | |
52 Neutral | $5.24B | 3.76 | -41.88% | 2.85% | 17.01% | 0.78% | |
47 Neutral | $335.02M | ― | -84.50% | ― | -16.27% | ― | |
45 Neutral | $28.52M | ― | -325.46% | ― | 51.62% | 62.14% |
Avicanna Earnings Call Summary
Avicanna Corporate Events
Avicanna Inc. announced the revocation of a Management Cease Trade Order by the Ontario Securities Commission, following the completion of all required filings. This development is expected to positively impact Avicanna’s operations by removing trading restrictions and potentially enhancing investor confidence, thereby strengthening its position in the biopharmaceutical industry.
Spark’s Take on TSE:AVCN Stock
According to Spark, TipRanks’ AI Analyst, TSE:AVCN is a Underperform.
Avicanna’s overall stock score reflects its strong revenue growth potential overshadowed by profitability challenges, financial instability, and bearish technical indicators. The company’s current valuation suggests distress, with no dividends and negative earnings, highlighting significant risks for investors.
To see Spark’s full report on TSE:AVCN stock, click here.
Avicanna reported a successful financial year in 2024, with a 52% increase in revenue to $25.5 million and a 94% rise in gross profits to $12.9 million. The company achieved self-sufficiency and improved its financial foundation, setting the stage for further growth and international expansion. Significant advancements included the initiation of a medical cannabis study in Canada, the completion of studies on cannabinoid products for various health conditions, and the approval of Trunerox™ in Colombia for treating rare epileptic disorders. These developments enhance Avicanna’s industry positioning and offer promising implications for stakeholders.
Spark’s Take on TSE:AVCN Stock
According to Spark, TipRanks’ AI Analyst, TSE:AVCN is a Underperform.
Avicanna’s overall stock score reflects its strong revenue growth potential overshadowed by profitability challenges, financial instability, and bearish technical indicators. The company’s current valuation suggests distress, with no dividends and negative earnings, highlighting significant risks for investors.
To see Spark’s full report on TSE:AVCN stock, click here.
Avicanna Inc. has received approval for a management cease trade order (MCTO) from the Ontario Securities Commission due to delays in filing its 2024 audited financial statements. The delay is attributed to personnel and licensing issues with the company’s auditors, which are expected to be resolved shortly. The MCTO restricts trading by insiders but does not affect other investors. Avicanna assures stakeholders that the delay is not material to its operations, and the company continues to function normally, with no insolvency proceedings or undisclosed material changes.
Spark’s Take on TSE:AVCN Stock
According to Spark, TipRanks’ AI Analyst, TSE:AVCN is a Underperform.
Avicanna’s overall stock score reflects its strong revenue growth potential overshadowed by profitability challenges, financial instability, and bearish technical indicators. The company’s current valuation suggests distress, with no dividends and negative earnings, highlighting significant risks for investors.
To see Spark’s full report on TSE:AVCN stock, click here.
Avicanna announced its 5th medical symposium on cannabinoid-based medicine, scheduled for June 6, 2025, at the MaRS Discovery District in Toronto. The event will gather healthcare practitioners and researchers to discuss the latest developments and clinical practices in cannabinoid medicine, featuring speakers from leading academic and clinical organizations. The symposium aims to enhance understanding and foster collaboration within the medical community, with opportunities for attendees to present research findings through poster sessions.
Spark’s Take on TSE:AVCN Stock
According to Spark, TipRanks’ AI Analyst, (TSE:AVCN) is a Underperform.
Avicanna’s overall stock score reflects its strong revenue growth potential overshadowed by profitability challenges, financial instability, and bearish technical indicators. The company’s current valuation suggests distress, with no dividends and negative earnings, highlighting significant risks for investors.
To see Spark’s full report on (TSE:AVCN) stock, click here.
Avicanna announced a delay in filing its audited consolidated financial statements for the year ended December 31, 2024, due to auditor licensing and personnel issues. The company has applied for a Management Cease Trade Order with the Ontario Securities Commission to prohibit management from trading securities until the documents are filed, expected by April 15, 2025. This delay also affects the 2024 Full Year Earnings Conference Call, which has been postponed. The situation highlights potential operational and regulatory challenges for Avicanna, impacting its financial transparency and stakeholder confidence.
Avicanna Inc. announced it will hold a conference call to discuss its Full Year 2024 financial results, which will be filed after the market closes on March 31, 2025. This announcement highlights Avicanna’s ongoing commitment to transparency and communication with its stakeholders, potentially impacting its market positioning and investor relations positively.